The Development of New Molecules Having Antiemetic Activity Using Molecular Modeling
Khalil Errahmane Kanouni1 & Yacine Benguerba2 Show affiliations
- Sétif-1-University, Algeria
- Centre de Recherche en Biotechnologie (CRBt), Algeria
Current Research in Bioinformatics, Volume 8, Issue 1, pp. 21–28 · doi.org/10.3844/ajbsp.2019.21.28
Abstract
The solubility of a drug in water or in the blood represents the most desired parameter in medicine. Our aim is to obtain molecules with properties more effective than those of metoclopramide. In this work, two molecules with high solubility are constructed. Metoclopramide (a benzamide derivative) is a dopamine receptor antagonist used as an antiemetic drug. Its solubility in water is 200 mg/L at 25°C. In this work, we will develop two other molecules that have the same therapeutic activity of metoclopramide with a higher solubility in water, therefore in the blood, without affecting the other properties. The two molecules developed by molecular modeling with a chemical modification of the OH group of metoclopramide have a high solubility: approximately 3 times and 8 times that of metoclopramide. For the other physicochemical properties, there is a great similarity between the molecules. Thus, the two proposed molecules will have antiemetic activity, the second molecule will be more favorable because of its higher solubility and the number of HBA and HBD.
Licence and reuse
Open access. This article is licensed under a Creative Commons Attribution 3.0 Licence (CC BY 3.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.
How to reuse this articleResponses (0)
About this article
Kanouni, K. E. & Benguerba, Y. (2019). The Development of New Molecules Having Antiemetic Activity Using Molecular Modeling. Current Research in Bioinformatics, 8(1), 21–28. https://doi.org/10.3844/ajbsp.2019.21.28
- Licence
- CC BY 3.0
- Issue
- Volume 8, Issue 1
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record
